Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults.Antimicrobial agents and chemotherapy · 2015
   Trial
2. Model-based approach to sampling optimization in studies of antibacterial drugs for infants and young children.Clinical and translational science · 2021
   Article
3. Population Pharmacokinetic Model of Iohexol in Dogs to Estimate Glomerular Filtration Rate and Optimize Sampling Time.Frontiers in pharmacology · 2021
   Article
4. Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory.Pharmaceutical research · 2018
   Article
5. Assessing robustness of designs for random effects parameters for nonlinear mixed-effects models.Journal of pharmacokinetics and pharmacodynamics · 2017
   Article
6. Individual Bayesian Information Matrix for Predicting Estimation Error and Shrinkage of Individual Parameters Accounting for Data Below the Limit of Quantification.Pharmaceutical research · 2017
   Article
7. The effect of Fisher information matrix approximation methods in population optimal design calculations.Journal of pharmacokinetics and pharmacodynamics · 2016
   Article
8. Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Experiments in Mice.The AAPS journal · 2016
   Article
9. A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail.European journal of clinical pharmacology · 2016
   Article
10. Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children.Clinical pharmacokinetics · 2015
    Review
11. Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology.Pharmaceutical research · 2015
    Article
12. Challenges and Opportunities for Exploring Patient-Level Data.BioMed research international · 2015
    Review
13. Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.British journal of clinical pharmacology · 2015
    Article
14. Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.British journal of clinical pharmacology · 2014
    Article
15. Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome.CPT: pharmacometrics & systems pharmacology · 2013
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

8 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.